The New York Times on Tuesday May 14 contained an op-ed by Angelina Jolie, the actress and director. In it she discloses that she has a family history of breast cancer and that she decided to have a double mastectomy before cancer developed. I have written about this as a patent issue in the past, talking about the Myriad case before the United States Supreme Court, but Ms Jolie’s op-ed puts a personal and familiar face to the problem of genetic issues and patent protection.
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
Anita Cade, head of Ashurst’s IP and media team in Australia, discusses why law firms that can pull together capability across different practice areas and jurisdictions stand to gain
INTA’s CEO says London-based firms have registered fewer delegates compared to past meetings in San Diego and Atlanta, and questions the 'ethics' of trying to participate without registering
News of a trademark row over Taylor Swift’s ‘The Life of a Showgirl’ and Nokia’s expansion of its IoT licensing programme were also among the top talking points
IP attorneys share how the Cox v Sony ruling impacts their counselling strategies, and if the case could influence how courts may assess liability for AI platforms
Natasha Daughtrey shares how firms can help their women litigators take the lead on trials, and why she is seeing a convergence of tech and life sciences disputes